Union Hospital of Huazhong University of Science and Technology to Transfer Cervical Cancer Radiotherapy-Sensitizing Nanotechnology for RMB 305,000

Recently, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology (hereinafter referred to as “Union Hospital”) released a public notice on the transformation of scientific and technological achievements. The hospital intends to transfer a technology named“A Biomimetic MOF Nanoplatform Capable of Dual-Targeting Cervical Cancer Tumor Cells and Cancer-Associated Fibroblasts for Co-Delivery of FAK Inhibitors and Bismuth, and Its Preparation Method and Application”invention patent, assigned toWuhan LvDong Technology Co., Ltd., the agreed price isRMB 305,000. The inventors of this patent are from the Department of Obstetrics and Gynecology, Peking Union Medical College HospitalMin Jie's Team。

The essence of the present invention is"A Biomimetic Nanomedicine Capable of Overcoming Radiotherapy Resistance in Cervical Cancer", its core function is to employ a specialized “Trojan horse” strategy—using cell membrane-coated nanocarriers to achieve dual targeting of tumor cells and cancer-associated fibroblasts (CAFs). This approach enhances radiation-induced cytotoxicity while suppressing recurrence by remodeling the tumor microenvironment, thereby providing a novel solution for radiosensitization in patients with advanced cervical cancer.

As the fourth most common malignant tumor among women worldwide, cervical cancer has long been a focal point of prevention and treatment efforts. For patients with advanced or locally advanced cervical cancer, concurrent chemoradiotherapy (CCRT) is currently recognized as the standard clinical treatment regimen. However, clinical data indicate that approximately 30% of patients still experience recurrence after receiving standard radiotherapy, primarily due to the development of "radioresistance" by the tumor itself. Overcoming this resistance mechanism and enhancing radiosensitivity are key to improving patient prognosis and extending survival.

In the microscopic world of tumor growth, the efficacy of radiotherapy is often severely constrained by the complex “tumor microenvironment.” This environment is not merely a cluster of cancer cells, but a complex ecosystem replete with physiological barriers, including hypoxia, abnormal vasculature, and a dense extracellular matrix.

EspeciallyCAFs, in which they play the role of "accomplices." CAFs synthesize large amounts of extracellular matrix, constructing a dense physical barrier around the tumor. This barrier not only hinders drug penetration but also leads to intratumoral hypoxia—oxygen being a critical cofactor for the cytotoxic effects of radiation. In various malignancies, including lung and breast cancer, CAFs have been confirmed as major contributors to radiotherapy resistance.

Although current clinical radiotherapy utilizes ionizing radiation to eradicate local tumors, it often proves inadequate when confronting the “impregnable barrier” constructed by cancer-associated fibroblasts (CAFs). Conventional radiotherapy strategies struggle to precisely eliminate these stromal cells that protect the tumor and fail to effectively reverse the hypoxic state within the tumor microenvironment. This discrepancy between the therapeutic approach and the physiological barriers of the microenvironment results in a risk of recurrence for some patients, despite their endurance of arduous treatment.

Therefore, there is an urgent clinical need for a novel strategy to break this impasse—one that can precisely target tumor cells while dismantling their underlying “protective umbrella.” By reversing the tumor microenvironment through this dual-pronged approach, the sensitivity of cervical cancer to radiotherapy can be fundamentally enhanced.

It is precisely the clinical challenge of radiotherapy resistance in cervical cancer that has driven Min Jie’s team to pursue innovative explorations in the field of nanomedicine. This patented technology—“Can simultaneously target cervical cancer tumor cells and cancer-associated fibroblasts, and co-deliver a FAK (focal adhesion kinase) inhibitor and IZB@CCM (a bismuth-based biomimetic MOF nanoplatform)”, it did not stop at traditional drug improvement, but instead constructed a precise, intelligent, and efficient "combination therapy" for anti-tumor treatment by deeply integrating "biomimetic camouflage technology" with "microenvironment remodeling strategies."

This approach pioneers a breakthrough in the “precise navigation” of drug delivery. Traditional nanomedicines often fail to reach lesion sites due to recognition and clearance by the immune system. To address this, Min Jie’s team innovatively developed a “hybrid membrane” camouflage technology. They physically fused cervical cancer tumor cell membranes with cancer-associated fibroblast (CAF) membranes, cloaking the nanocarriers in a “Trojan horse” disguise. This biomimetic camouflage confers unique homotypic targeting capabilities, enabling the drug not only to evade immune surveillance but also to precisely recognize and accumulate around tumor cells and CAFs, thereby fundamentally resolving the long-standing challenges of poor drug penetration and retention.

Under the premise of achieving precise localization, IZB@CCM further“Physical Sensitization + Biological Remodeling”dual mechanism to enhance therapeutic efficacy. It employs intelligent degradation in acidic environmentsZIF-8 Metal–Organic Framework, and equipped with dual "weapons":First, bismuth (Bi) with a high atomic number, acting as an "amplifier" for radiotherapy, can significantly enhance the efficiency of tumor absorption of X-rays, thereby directly increasing physical cytotoxicity;Second, the small-molecule drug IN10018, as a highly efficient FAK inhibitor, IN10018 acts as a “biological wall-breaker.” The FAK protein is typically a key signaling molecule mediating the “adhesion” between tumor cells and the surrounding stroma. By specifically blocking this signaling pathway, IN10018 can effectively inhibit the activity of cancer-associated fibroblasts (CAFs) and reduce the deposition of the protective extracellular matrix.

Upon entering the slightly acidic tumor microenvironment, the nanoparticles rapidly disintegrate and release their drug payload. IN10018 subsequently blocks signaling pathways, inhibits the activity of cancer-associated fibroblasts (CAFs), and reduces extracellular matrix deposition, effectively dismantling the “physical barrier” that protects the tumor and alleviating internal hypoxia. This design ingeniously achieves a synergistic effect where “1+1>2”: on one hand, bismuth elements directly enhance radiation-induced damage; on the other, the inhibitor disrupts the protective network formed by CAFs. This technology upgrades traditional “passive radiotherapy” to a precise therapeutic model characterized by “active sensitization and microenvironment remodeling,” holding promise for significantly improving radiosensitivity in patients with advanced cervical cancer and paving new avenues for better prognoses.

Currently, the global field of tumor radiosensitization is at a critical inflection point for technological iteration. Although traditional chemotherapeutic agents such as cisplatin remain the mainstream clinical radiosensitizers, their severe systemic toxicities and increasingly prevalent drug resistance have prompted both the research community and industry to turn their attention toward more precise and less toxic nanotechnologies. Presently, related research and development are exhibiting a dual-track competitive landscape, with parallel advances in “physical sensitization” and “biological modulation.”

InPhysical SensitizationTrack, withFrench Nanobiotix CompanyR&DNBTXR3as a representative product. This is a functionalized hafnium oxide nanoparticle that has currently entered clinical trials in multiple regions worldwide. The core mechanism of NBTXR3 leverages the high atomic number of hafnium to physically enhance radiation energy deposition within tumors. However, such physical radiosensitizers typically rely on intratumoral injection to ensure adequate concentration and lack active targeting capabilities for systemic administration. Furthermore, the singular physical sensitization mechanism is insufficient to actively reverse the dense stromal barrier constructed by cancer-associated fibroblasts (CAFs). Consequently, there remains room for improvement in terms of penetration and biological efficacy for advanced cervical cancer, which is characterized by abundant stroma and severe hypoxia.

InBiological RegulationIn this arena, targeted therapies against the FAK signaling pathway are also a current research hotspot. For example,InxMedDevelopedIN10018Multiple clinical trials are underway to modulate the tumor immune microenvironment by inhibiting FAK. However, small-molecule inhibitors often carry the risk of “off-target” side effects upon systemic administration and, constrained by the dense stromal pressure within tumors, struggle to achieve ideal accumulation concentrations at the core of the lesion. More importantly, the use of biological inhibitors alone lacks the physical radiosensitizing effect necessary to maximize cytotoxic efficacy within the brief therapeutic window of radiotherapy.

In contrast, the IZB@CCM nanoplatform developed by Min Jie’s team at Peking Union Medical College Hospital is not a simple combination of the two aforementioned approaches, but rather achieves a deep integration of “physical + biological” mechanisms. Compared with similar competing products that rely solely on passive physical sensitization, IZB@CCM demonstrates significant “dimensional elevation” advantages:It not only introduces Bi as the sensitizing core but also equips the drug with an “automatic navigation system” by leveraging a unique dual-biomimetic hybrid membrane.

This design endows the nanoparticles with the potential to precisely target lesions under systemic administration conditions, enabling them to actively remodel the complex matrix microenvironment. Compared with biologics used alone, IZB@CCM leverages a metal-organic framework (MOF) carrier to achieve high-capacity loading of IN10018 and intelligent, microenvironment-responsive release. This approach effectively reduces systemic toxicity and side effects, while successfully realizing an integrated synergy of “matrix barrier disruption” and “radiation-induced killing” through the potent combination of a biological inhibitor and a physical radiosensitizer.